carvedilol has been researched along with Kidney Diseases in 13 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study)." | 6.25 | Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. ( Beck, GJ; Berl, T; Chartyan, DM; Cheung, AK; Chonchol, M; Cooper, C; Henrich, WL; Himmelfarb, J; Iyengar, M; Lukas, MA; Wali, RK; Weir, MR, 2011) |
| "This prospective post-marketing drug use survey was conducted to assess the safety and efficacy of the β-adrenergic receptor antagonist (β-blocker) Artist® Tablets (carvedilol) in patients with hypertension in Japan." | 3.77 | Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. ( Hiramatsu, K; Iizuka, T; Komiya, M; Matsumoto, T; Mori, Y; Nishikawa, Y; Zenimura, N, 2011) |
| "A total of 114 dialysis patients with dilated cardiomyopathy were randomized to receive either carvedilol or placebo in addition to standard therapy." | 2.71 | Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. ( Calabrò, R; Cice, G; Cittadini, A; D'Andrea, A; D'Isa, S; Di Benedetto, A; Ferrara, L; Golino, P; Russo, PE, 2003) |
| "Carvedilol was given at a dose of 2 mg/kg and nebivolol at a dose of 1 mg/kg by way of oral gavage." | 1.42 | The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats. ( Akgüllü, Ç; Boyacıoğlu, M; Eryılmaz, U; Güngör, H; Hekim, T; Karul, A; Meteoğlu, İ; Onbaşılı, OA, 2015) |
| "Carvedilol was able to counteract the renal damage by preventing the mitochondrial dysfunction induced by cisplatin." | 1.36 | Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. ( Barbosa, F; Curti, C; Martins, NM; Rodrigues, JL; Rodrigues, MA; Santos, AC; Santos, NA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, D | 1 |
| Yang, H | 1 |
| Li, Q | 1 |
| Bae, HJ | 1 |
| Obianom, O | 1 |
| Zeng, S | 1 |
| Su, T | 1 |
| Polli, JE | 1 |
| Shu, Y | 1 |
| Akgüllü, Ç | 2 |
| Eryılmaz, U | 2 |
| Güngör, H | 2 |
| Huyut, A | 1 |
| Zencir, C | 1 |
| Hekim, T | 2 |
| Boyacıoğlu, M | 1 |
| Meteoğlu, İ | 1 |
| Karul, A | 1 |
| Onbaşılı, OA | 1 |
| Jovanovic, D | 1 |
| Jovovic, D | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Miloradovic, Z | 1 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 1 |
| Maksic, N | 1 |
| Djukanovic, L | 1 |
| Rodrigues, MA | 2 |
| Rodrigues, JL | 2 |
| Martins, NM | 2 |
| Barbosa, F | 2 |
| Curti, C | 2 |
| Santos, NA | 2 |
| Santos, AC | 2 |
| Ito, H | 1 |
| Nagatomo, Y | 1 |
| Kohno, T | 1 |
| Anzai, T | 1 |
| Meguro, T | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Wali, RK | 1 |
| Iyengar, M | 1 |
| Beck, GJ | 1 |
| Chartyan, DM | 1 |
| Chonchol, M | 1 |
| Lukas, MA | 1 |
| Cooper, C | 1 |
| Himmelfarb, J | 1 |
| Weir, MR | 1 |
| Berl, T | 1 |
| Henrich, WL | 1 |
| Cheung, AK | 1 |
| Mori, Y | 1 |
| Nishikawa, Y | 1 |
| Iizuka, T | 1 |
| Zenimura, N | 1 |
| Matsumoto, T | 1 |
| Hiramatsu, K | 1 |
| Komiya, M | 1 |
| Padi, SS | 1 |
| Chopra, K | 2 |
| Cice, G | 1 |
| Ferrara, L | 1 |
| D'Andrea, A | 1 |
| D'Isa, S | 1 |
| Di Benedetto, A | 1 |
| Cittadini, A | 1 |
| Russo, PE | 1 |
| Golino, P | 1 |
| Calabrò, R | 1 |
| Singh, D | 1 |
| Chander, V | 1 |
| Salplachta, J | 1 |
| Strnadová, V | 1 |
| Csöllei, J | 1 |
1 review available for carvedilol and Kidney Diseases
| Article | Year |
|---|---|
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
2 trials available for carvedilol and Kidney Diseases
| Article | Year |
|---|---|
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-U | 2003 |
11 other studies available for carvedilol and Kidney Diseases
| Article | Year |
|---|---|
Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
Topics: Animals; Antineoplastic Agents; Carvedilol; Cell Survival; Cisplatin; HEK293 Cells; Humans; Kidney; | 2018 |
A clinical study about contrast nephropathy: risk factors and the role of beta blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contrast Media; Cross-Sectional Studies; Female | 2015 |
The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Contrast Media; Diatrizoate; | 2015 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Antioxidants; Calcium; Carbazoles; Carvedil | 2010 |
Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; Carvedilol; Drug Evaluation; Female; Glome | 2010 |
Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Blood Urea Nitrogen; Carbazoles; Carvedilol | 2011 |
Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and ove | 2011 |
Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Cyclosporine; Disease Mo | 2002 |
Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats.
Topics: Animals; Antioxidants; Blood Urea Nitrogen; Carbazoles; Carcinogens; Carvedilol; Catalase; Creatinin | 2003 |
[Effect of Consupren, Carvedilol and BL-443 on the composition of lactate dehydrogenase in tissues of rats with cyclosporin nephropathy].
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Carbamates; Carbazoles; Carvedilol; Cyclos | 2002 |